Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, TRI

Anju to Exhibit and Present at EUCROF24: Leveraging Data for Enhanced Site Selection and Feasibility in Clinical Trials


FORT LAUDERDALE, Fla., Feb. 16, 2024 /PRNewswire/ -- Anju Software, a leading provider of software solutions for the life sciences industry, is pleased to announce its participation in EUCROF's (the European CRO Federation) annual conference. Elke Ydens, Associate Director of Business Solutions at Anju, will deliver a compelling presentation titled "Clinical Use Case: Why You Need a Data-Driven Approach for Site Selection and Feasibility."

Scheduled for Monday, February 19, at 2 PM CET, Elke's presentation will delve into the complexities of trial planning and the necessity for precision in every phase of the clinical process. She will emphasize the transformative power of data-driven insights in overcoming these complexities and achieving impactful results.

In the dynamic realm of clinical research, data-driven site selection and feasibility assessments are integral for optimizing trial timelines and results. Elke will cover topics including extracting insights from historical data, navigating the competitive landscape's impact on strategic decisions, and aligning site selection with diversity strategies. The presentation will provide actionable guidance for implementing a data-driven approach to trial planning, emphasizing steps like utilizing historical data, assessing competitive landscapes, setting patient enrollment benchmarks, and identifying sites with capacity to recruit a diverse patient population.

"We are excited to share our expertise in data-driven approaches for optimizing site selection and feasibility in clinical trials," said Elke Ydens. "By harnessing the power of data and analytics, organizations can navigate the complexities of trial planning more effectively, driving improved outcomes."

Attendees of EUCROF24 are encouraged to join Elke's session to gain valuable insights into enhancing trial planning processes through data-driven methodologies. Visit Anju's booth #2 throughout the conference to learn more about Anju and its innovative solutions for the life sciences industry or visit www.anjusoftware.com.

About Anju Software
Anju is a customer-first organization delivering adaptable life science solutions for clinical research, medical affairs, and data science. TrialMaster, IRMS MAX, and TA Scan, the company's flagship products, lead the way in reducing complexities in the drug and device discovery and commercialization process. With a team of industry experts and a diverse suite of versatile products, Anju empowers clients to drive innovation, efficiency, and compliance. Anju is a portfolio company of Abry Partners serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.

Media Contact
John F. Kouten
JFK Communications, Inc.
+1 609.241.7352
[email protected]

SOURCE Anju Software


These press releases may also interest you

at 05:40
Join Ekran System for an Insightful Webinar With Jonathan Care, an Established Cybersecurity Expert and Former Gartner Analyst, Who Will Unveil Powerful Strategies for Optimizing Third-party Vendor Monitoring
Ekran System, a top insider risk management solutions provider, together with Jonathan Care, cybersecurity expert and former Gartner analyst, will host a webinar titled "Effective Third-Party Vendor Monitoring Strategies." Scheduled to take place...

at 05:38
VTech Announces FY2024 Annual Results
Group revenue declined by 4.3% to US$2,145.7 millionGross profit margin improved from 28.3% to 29.6%Profit attributable to shareholders of the Company rose by 11.7% to US$166.6 millionFinal dividend of US48.0 cents per ordinary share, resulting in a...

at 05:35
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA's 84th Scientific Sessions
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that its abstract of preclinical data evaluating an mRNA-based GLP-1R agonist (HFG1) in diabetic...

at 05:35
Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of the dangers of...

at 05:30
Alpha Match Brings Best-Execution and Efficiency to the Fund Finance Market Against a Backdrop of Increased Regulation and LP Scrutiny
Alpha Group International plc (LON:ALPH) today announced the launch of Alpha Match. Alpha Match is Alpha's digital debt intermediary service. It is disrupting the fund finance industry with its impartial database of more than 290 lenders ? making the...

at 05:30
European CEO names Evgen Belousov Chief Executive Officer of the year in the iGaming industry
Evgen Belousov, head of iGaming provider GR8 Tech, has been named Chief Executive Officer of the Year in the iGaming Industry by European CEO magazine. Belousov launched GR8 Tech in January 2023, offering "tailored, flexible and scalable" sportsbook...

More news about Science and technology...


News published on and distributed by: